Curriculum vitae

Dr. med. Livius Penter +49 (0)30 450 553 615

Forum 4, Raum 1.0523 Augustenburger Platz 1 13353 Berlin

Germany

Livius.Penter@charite.de

© 0000-0002-9060-0207

Born October 02, 1987 in Dresden, Germany

Married

www.penterlab.org



Research

	Charité – Universitätsmedizin Berlin, Germany
Since 10/2023	Max-Eder Research Group leader Cancer and immune cell co-evolution
	Dana-Farber Cancer Institute, USA
10/2019 – 09/2023	Postdoctoral research fellow (Wu Lab) CTLA-4 blockade for relapsed myeloid malignancies after transplantation
	Charité – Universitätsmedizin Berlin, Germany
06/2015 – 09/2019	Postdoctoral research fellow (Hansmann Lab) Immunologic biomarkers and therapeutic targets in rectal cancer
	Laboratory of Pediatric Molecular Biology Berlin, Germany
08/2009 – 05/2015	Medical thesis (Prof. Hagemeier) Development of a lentiviral shRNA screen in SH-EP neuroblastoma cells
	Research Institute of Molecular Pathology Vienna, Austria
06 – 08/2013	Vienna Biocenter Summer School (Zuber Lab)
	Max Planck Institute of Molecular Cell Biology Dresden, Germany
09/2005 - 06/2007	School project: Phylogenetic analysis of proteins using bioinformatics tools

Education

	Berlin Institute of Health
10/2023 - 09/2026	Digital Clinician Scientist
	Berlin Institute of Health
07/2016 to 07/2018	Junior Clinician Scientist
	Charité – Universitätsmedizin Berlin
01/2015 - 09/2019	Internal Medicine and Hematology/Oncology
05/2015	Medical thesis with grade 1.0 (magna cum laude)
11/2014	Medical state examination with grade 1.33 (1.0=best, 5.0=bottom)
	Martin-Andersen-Nexö-Gymnasium Dresden, Germany
06/2007	High school diploma with grade 1.0 (1.0=best, 6.0=bottom) Prizes in informatics competitions and work as administrator of computer pool

International experience

McGill University Montreal, Canada

02 – 04/2014 Clinical electives in cardiology and nephrology

Université Diderot Paris VII, France

09/2013 – 02/2014 Clinical electives in general surgery and medical oncology

Université Pierre et Marie Curie Paris VI, France

08/2011 – 06/2012 ERASMUS exchange

Bangalore Baptist Hospital, India

02 – 03/2010 Clinical elective in general surgery

Morrin High School, Alberta, Canada

09/2004 – 06/2005 High school diploma

Scholarships and awards

10/2023 – 09/2026 Berlin Institute of Health – Digital Clinician Scientist Grant

01-06/2023 EHA-EMBL/EBI Computational Biology Training in Hematology (CBTH)

07/2022 ASH Scholar Award

12/2020 and 12/2021 ASH Achievement Award

10/2019 – 03/2022 German Research Foundation (DFG) – Research Fellowship 07/2016 – 06/2018 Berlin Institute of Health – Junior Clinician Scientist Grant

09/2013 – 04/2014 German Academic Exchange Service (DAAD) – Exchange Scholarship

08/2013 Vienna Biocenter – VWR Summer School Prize

05/2010 – 11/2014 German Academic Scholarship Foundation – University Scholarship

Languages spoken

German native

English near-native (C2)
French proficient (C1)
Romanian proficient (C1)

Selected Publications

Dana-Farber Cancer Institute (since 2019)

Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease **Penter L**, Liu Y, Wolff JO, Yang L, Taing L, Jhaveri A, Southard J, Patel M, Cullen NM, Pfaff KL, Cieri N, Oliveira G, Kim-Schulze S, Ranasinghe S, Leonard R, Robertson T, Morgan EA, Chen HX, Song MH, Thurin M, Li S, Rodig SJ, Cibulskis C, Gabriel S, Bachireddy P, Ritz J, Streicher H, Neuberg DS, Hodi FS, Davids MS, Gnjatic S, Livak KJ, Altreuter J, Michor F, Soiffer RJ, Garcia JS, Wu CJ

Blood. 2023 Apr 13;141(15):1817-1830. IF 25.5

Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models **Penter L***, ten Hacken E*, Southard J, Lareau CA, Ludwig LS, Li S, Neuberg DS, Livak KJ, Wu CJ Cancer Research. 2023 Mar 2;83(5):667-672. **IF 12.7**

AML relapse after a TIGIT race

Penter L. Wu CJ

Blood. 2022 Sep 15;140(11):1189-1191. IF 25.5

Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics

Penter L, Gohil SH, Wu CJ

Frontiers in Immunology. 2022 12:788891. IF 7.6

Coevolving JAK2V617F⁺ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case

Penter L, Gohil SH, Huang T, Thrash EM, Schmidt D, Li S, Severgnini M, Neuberg DS, Hodi FS, Livak KJ, Zeiser R, Bachireddy P, Wu CJ

Blood Advances. 2021 5(22):4701-4709. IF 6.7

Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history

Penter L*, Gohil SH*, Lareau C, Ludwig LS, Parry EM, Huang T, Li S, Zhang W, Livitz D, Leshchiner I, Parida L, Getz G, Rassenti LZ, Kipps TJ, Brown JR, Davids MS, Neuberg DS, Livak KJ, Sankaran VG, Wu CJ. Cancer Discovery. 10.1158/2159-8290.CD-21-0276. 2021 **IF 39.4**

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Penter L, Zhang Y, Savell A, Huang T, Cieri N, Thrash EM, Kim-Schulze S, Jhaveri A, Fu J, Ranasinghe S, Li S, Zhang W, Hathaway ES, Nazzaro M, Kim HT, Chen H, Thurin M, Rodig SJ, Severgnini M, Cibulskis C, Gabriel S, Livak KJ, Cutler C, Antin JH, Nikiforow S, Koreth J, Ho VT, Armand P, Ritz J, Streicher H, Neuberg D, Hodi FS, Gnjatic S, Soiffer RJ, Liu XS, Davids MS, Bachireddy P, Wu CJ.

Blood. 2021 137 (23), 3212-3217. IF 22.1

Personal tumor antigens in blood malignancies: genomics-directed identification and targeting **Penter L**, Wu CJ

JCI. 2020 130 (4), 1595-1607. IF 14.8

<u>Charité – Universitätsmedizin Berlin (2015 – 2019)</u>

Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer

Penter L, Dietze K, Ritter J, Lammoglia-Cobo MF, Garmshausen J, Aigner F, Bullinger L, Hackstein H, Wienzek-Lischka S, Blankenstein T, Hummel M, Dornmair K, Hansmann L.

Oncolmmunology. 2019 8 (6), e1586409. IF 5.9

FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells **Penter L**, Dietze K, Bullinger L, Westermann J, Rahn HP, Hansmann L.

Eur J Immunol. 2018 Jul;48(7):1248-1250. IF 4.3

A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma

Penter L, Maier B, Frede U, Hackner B, Carell T, Hagemeier C, Truss M.

Target Oncol. 2015 Dec;10(4):523-33. IF 4.7